WHO ICTRP trial
A multicenter, randomized, double-blind study to compare the effects of 24 weeks…
EUCTR2005-000473-22-SK · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-000473-22-SK |
|---|---|
| Public title | A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes |
| Scientific title | A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes |
| Primary sponsor | Novartis Pharma Services AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Therapeutic exploratory (Phase II): Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): |
| Countries | Slovakia |
| Conditions | Type II Diabetes MedDRA version: 7.1 Classification code 10045242 |
| Interventions | Product Code: LAF237 Pharmaceutical Form: Tablet INN or Proposed INN: vildagliptinum CAS Number: 274901-16-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet… |
| Registration date | May 8, 2005 |
| Target size | 344 |
| Secondary IDs | CLAF237A2384 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: